Finance

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma

Dateline City:
PRINCETON, N.J.

Results show overall response rates of 65% or greater with median follow-up of at least 16 months, regardless of prior brentuximab vedotin therapies

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers
Squibb Company
(NYSE:BMY) today announced extended follow-up data in
which Opdivo (nivolumab) demonstrated responses in adult patients
with relapsed or progressed classical Hodgkin lymphoma (cHL) after
autologous stem cell transplant (ASCT), irrespective of brentuximab
vedotin (BV) therapy history. Results from the Phase 2 CheckMate -205
study reflect the longest follow-up data of a programmed death 1 (PD-1)
inhibitor in patients with cHL.

Ticker Slug:

$BMY to announce extended follow-up data in classical Hodgkin #lymphoma at #ICML17

read more

Copyright © 2015 A Daily News.

To Top